Compare Procter & Gamble Health with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs VENUS REMEDIES - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH VENUS REMEDIES PROCTER & GAMBLE HEALTH/
VENUS REMEDIES
 
P/E (TTM) x 51.9 -1.1 - View Chart
P/BV x 4.7 0.1 6,346.0% View Chart
Dividend Yield % 10.1 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   VENUS REMEDIES
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
VENUS REMEDIES
Mar-18
PROCTER & GAMBLE HEALTH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,549126 2,818.9%   
Low Rs1,30161 2,129.8%   
Sales per share (Unadj.) Rs511.4301.8 169.5%  
Earnings per share (Unadj.) Rs61.3-24.9 -246.4%  
Cash flow per share (Unadj.) Rs74.02.5 2,908.6%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.8293.3 316.3%  
Shares outstanding (eoy) m16.6012.34 134.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,530.5%   
Avg P/E ratio x39.6-3.8 -1,052.5%  
P/CF ratio (eoy) x32.836.7 89.2%  
Price / Book Value ratio x2.60.3 819.9%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,2571,154 3,489.2%   
No. of employees `0001.10.9 122.6%   
Total wages/salary Rs m1,313393 333.9%   
Avg. sales/employee Rs Th7,486.74,026.1 186.0%   
Avg. wages/employee Rs Th1,157.6425.0 272.4%   
Avg. net profit/employee Rs Th897.2-331.8 -270.4%   
INCOME DATA
Net Sales Rs m8,4903,724 228.0%  
Other income Rs m24423 1,084.0%   
Total revenues Rs m8,7343,747 233.1%   
Gross profit Rs m1,482395 375.3%  
Depreciation Rs m211338 62.4%   
Interest Rs m0354 0.0%   
Profit before tax Rs m1,514-275 -550.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m56332 1,780.1%   
Profit after tax Rs m1,017-307 -331.5%  
Gross profit margin %17.510.6 164.6%  
Effective tax rate %37.1-11.5 -323.6%   
Net profit margin %12.0-8.2 -145.4%  
BALANCE SHEET DATA
Current assets Rs m15,3432,638 581.7%   
Current liabilities Rs m1,9602,305 85.1%   
Net working cap to sales %157.68.9 1,762.7%  
Current ratio x7.81.1 683.9%  
Inventory Days Days49135 36.0%  
Debtors Days Days2846 61.4%  
Net fixed assets Rs m1,2094,871 24.8%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m15,2353,496 435.8%   
Net worth Rs m15,4013,619 425.6%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m17,5957,509 234.3%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.5 97.3%   
Return on assets %5.80.6 916.0%  
Return on equity %6.6-8.5 -77.9%  
Return on capital %10.31.6 648.4%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m1,6360-   
Fx outflow Rs m4,368517 845.7%   
Net fx Rs m-2,732-517 528.9%   
CASH FLOW
From Operations Rs m-1,304514 -253.5%  
From Investments Rs m12,697-123 -10,314.5%  
From Financial Activity Rs m-301-387 77.6%  
Net Cashflow Rs m11,0934 264,116.7%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.2 10,111.1%  
FIIs % 1.0 0.6 172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 66.4 43.8%  
Shareholders   28,591 20,121 142.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 17, 2019 02:01 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS